Status:
RECRUITING
Inhaled Treprostinil for Dyspnea and Exercise Intolerance in Mild COPD
Lead Sponsor:
University of Alberta
Conditions:
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility:
All Genders
50-85 years
Phase:
PHASE2
Brief Summary
The goal of this clinical trial is to evaluate the impact of inhaled Treprostinil on breathlessness and low exercise capacity in patients living with mild chronic obstructive pulmonary disease. Partic...
Detailed Description
The study consists of 6 visits (5 to the Clinical Sciences Building at the University of Alberta): Day 1: participants will provide informed consent, medical history and health screening (Physical ac...
Eligibility Criteria
Inclusion
- Patients with mild COPD (defined as having a postbronchodilator FEV1/FVC ratio \<0.70 and FEV1 ≥ 80% predicted
Exclusion
- Pre-existing heart failure and pulmonary artery hypertension.
- Known thrombocytopenia.
- Resting blood pressure of \<90mmHg systolic and \<50 mmHg diastolic.
- Known sensitivity to prostanoids
- Severe hepatic insufficiency
Key Trial Info
Start Date :
June 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06969573
Start Date
June 5 2025
End Date
December 31 2026
Last Update
December 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinical Physiology Laboratory
Edmonton, Alberta, Canada, T6G2R3